Imara is the second spin-out of rare disease incubator Cydan Development, Inc. Imara was formed to progress development of IMR-687, a PDE9 inhibitor for Sickle-Cell Disease (SCD). The program was acquired from Lundbeck Pharma. PDE9 works along a similar mechanistic pathway to the standard of care in SCD, Hydroxyurea, but has the potential for less side effects and improved tolerability. The drug is in Phase I clinical development.
Imara
